Regeneron Pharmaceuticals Inc
REGNHealthcare|Biotechnology|USA
$763.04
+1.19 (+0.16%)
DCF (FCF)
$641.30
Tangible Book
$283.77
Graham Number
$532.32
Earnings Power
$496.16
Analyst Ratings
| Firm / Analyst | Rating | Price Target | Date |
|---|---|---|---|
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — |
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812"
],
"revenue_estimate": [
15752.49,
17394.62,
18884.85
],
"ebit_estimate": [
5015.15,
6040.76,
6964.62
],
"ebitda_estimate": [
5274.47,
6036.49,
7008.17
],
"net_income_estimate": [
5029.24,
5927.04,
6653.34
],
"per_share_eps_estimate": [
39.01,
48.65,
56.13
],
"eps_nri_estimate": [
45.91,
54.02,
61.43
],
"dividend_estimate": [
3.36,
4.51,
4.93
],
"book_value_per_share_estimate": [
332.99,
375.47,
427.02
],
"pretax_income_estimate": [
5617.45,
6689.98,
7625.6
],
"operating_cash_flow_per_share_estimate": [
50.03,
55.59,
64.19
],
"roa_estimate": [
10.35,
11.6,
12.5
],
"roe_estimate": [
15.44,
14.67,
15.15
],
"gross_margin_estimate": [
84.28,
84.78,
84.94
],
"operating_cash_flow_estimate": [
5388.66,
5986.56,
6912.99
],
"pettm_estimate": [
19.56,
15.68,
13.6
],
"long_term_growth_rate_mean": 12.1,
"long_term_revenue_growth_rate_mean": "9.69",
"future_per_share_eps_estimate_growth": 11.94,
"future_eps_nri_estimate_growth": 12.1,
"future_revenue_estimate_growth": 9.69,
"future_ebit_estimate_growth": 10.74,
"future_ebitda_estimate_growth": 7.18,
"future_dividend_estimate_growth": 13.95,
"future_net_income_estimate_growth": 14.27,
"future_pretax_income_estimate_growth": 13.95,
"future_book_value_per_share_estimate_growth": 13.01,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 11.79
}
quarterly
{
"date": [
"202603",
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
3466.56,
3809.33,
4154.53,
4314.93,
4240.53,
4447.6,
4577.6,
4731.77
],
"ebit_estimate": [
976.65,
1196.85,
1488.22,
1509.01,
2990.91,
3251.36,
3557.62,
1408.46
],
"ebitda_estimate": [
1194.55,
1444.19,
1622.59,
1479.81,
1344,
1718,
1616.5,
1614
],
"net_income_estimate": [
977.15,
1153.32,
1369.53,
1405.41,
1298.09,
1435.25,
1494.22,
1517.21
],
"per_share_eps_estimate": [
8.43,
9.74,
11.54,
12.01,
9.89,
10.93,
11.46,
11.22
],
"eps_nri_estimate": [
9.09,
10.67,
12.67,
13.02,
11.87,
13.1,
13.63,
13.83
],
"dividend_estimate": [
0.88,
0.88,
0.88,
0.88,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
1117.32,
1350.34,
1581.97,
1613.38,
1592,
1800,
1848,
1849
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
83.67,
83.83,
84.2,
84.42,
85,
86,
87,
87
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
18.29,
17.67,
17.2,
17.23,
17.55,
null,
null,
null
],
"long_term_growth_rate_mean": 12.1,
"long_term_revenue_growth_rate_mean": "9.69",
"future_per_share_eps_estimate_growth": 11.94,
"future_eps_nri_estimate_growth": 12.1,
"future_revenue_estimate_growth": 9.69,
"future_ebit_estimate_growth": 10.74,
"future_ebitda_estimate_growth": 7.18,
"future_dividend_estimate_growth": 13.95,
"future_net_income_estimate_growth": 14.27,
"future_pretax_income_estimate_growth": 13.95,
"future_book_value_per_share_estimate_growth": 13.01,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 11.79
}